Michael Dybbs

Dr. Michael P.
Dybbs is an Independent Director at SpyGlass Pharma, Inc., an Independent Director at Kalaris Therapeutics, Inc., an Independent Director at Nkarta, Inc., an Independent Director at Sutro Biopharma, Inc., a Partner at Samsara BioCapital LLC and a Director & Investor at Fluent BioSciences, Inc. He is on the Board of Directors at SpyGlass Pharma, Inc., Kalaris Therapeutics, Inc., Nkarta, Inc., Sutro Biopharma, Inc., 565 SPV I LP, IONpath, Inc., Kalaris TX, Inc., Levo Therapeutics, Inc., Samsara BioCapital LP and Fluent BioSciences, Inc. Dr. Dybbs was previously employed as an Independent Director by Dimension Therapeutics, Inc., an Independent Director by Versartis, Inc., a Partner by New Leaf Venture Partners LLC, and a Principal by The Boston Consulting Group, Inc. He also served on the board at Principia Biopharma, Inc., Advanced Cell Diagnostics, Inc. and Rayzebio, Inc. He received his undergraduate degree from Harvard University and a doctorate degree from the University of California, Berkeley.